| | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.004.445 |
| Chemical and physical data | |
| Formula | C21H41N7O12 |
| Molar mass | 583.596 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Dihydrostreptomycin is semisynthetic aminoglycoside antibiotic with bactericidal properties. [1] It is the dihydro derivative of streptomycin, and was formerly used in the treatment of tuberculosis. [2]
It acts by irreversibly binding the S12 protein in the bacterial 30S ribosomal subunit, after being actively transported across the cell membrane, which interferes with the initiation complex between the mRNA and the bacterial ribosome. This leads to the synthesis of defective, nonfunctional proteins, which results in the bacterial cell's death. [2]
Dihydrostreptomycin is more ototoxic than streptomycin with a significantly higher risk of causing irreversible hearing loss, since streptomycin primarily affects vestibular system while dihydrostreptomycin primarily affects the cochlea. [3] [4] This lead to it being gradully pulled from market from 1959 and fully withdrawn from human use globally in 1970s. [5] [6] It remains a commonly used veterinary drug (usually in combination with penicillin G as an alternative to streptomycin) and agricultural bactericide. [7] [8]